# Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

> **NCT04145297** · PHASE1 · COMPLETED · sponsor: **University of Utah** · enrollment: 16 (actual)

## Conditions studied

- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** Ulixertinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04145297
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-17
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-08-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145297, "Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04145297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*